Abstract
Data on the basal (constitutive or spontaneous) activities of receptors, as well as their neurochemical and electrophysiological correlates, are presented. Inverse receptor agonists are a group of pharmacological drugs that can suppress constitutive activities. We describe the neurochemical mechanisms of the pharmacological activities of benzodiazepine binding site inverse agonists. These compounds inhibit chloride currents caused by gamma-aminobutyric acid at low non-physiological concentrations. This activity is the basis of the sobering action during the action of ethanol and the ability to suppress the addictive potential of psychoactive substances. In addition, the benzodiazepine binding site inverse agonists are able to activate memory formation processes and improve learning. The possible uses of drugs from this group in modern medicine are discussed. They may be used to treat a number of diseases in the fields of narcology, therapy, neurology, and psychiatry.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Atack, J.R., Maubach, K.A., Wafford, K.A., O’Connor, D., Rodrigues, A.D., Evans, D.C., Tattersall, F.D., and Chambers, M.S., Macleod A.M., Eng, W.S., Ryan, C., Hostetler, E., Sanabria, S.M., Gibson, R.E., Krause, S., Burns, H.D., Hargreaves, R.J., Agrawal, N.G., McKernan, R.M., Murphy, M.G., Gingrich, K., Dawson, G.R., Musson, D.G., and Petty, K.J., J. Pharmacol. Exp. Ther., 2009, vol. 331, no. 2, pp. 470–484.
Braudeau, J., Delatour, B., Duchon, A., Pereira, P.L., Dauphinot, L., de Chaumont, F., Olivo-Marin, J.C., Dodd, R.H., Hérault, Y., and Potier, M.C., J. Psychopharmacol., 2011, vol. 25, no. 8, pp. 1030–1042.
Sato, J., Makita, N., and Iiri, T., Endocr. J., 2016, vol. 63, no. 6, pp. 507–514.
Bhowmik, M., Khanam, R., and Vohora, D., Br. J. Pharmacol., 2012, vol. 167, no. 7, pp. 1398–1414.
Monczor, F., Fernandez, N., Fitzsimons, C.P., Shayo, C., and Davio, C., Eur. J. Pharmacol., 2013, vol. 715, nos. 1–3, pp. 26–32.
Corder, G., Doolen, S., Donahue, R.R., Winter, M.K., Jutras, B.L., He, Y., Hu, X., Wieskopf, J.S., Mogil, J.S., Storm, D.R., Wang, Z.J., McCarson, K.E., and Taylor, B.K., Science, 2013, vol. 341, no. 6152, pp. 1394–1399.
Polter, A.M., Barcomb, K., Chen, R.W., Dingess, P.M., Graziane, N.M., Brown, T.E., and Kauer, J.A., Elife, 2017, vol. 6, article e23785.
Arrang, J.M., Morisset, S., and Gbahou, F., Trends Pharmacol. Sci., 2007, vol. 28, no. 7, pp. 350–357.
Morisset, S., Rouleau, A., Ligneau, X., Gbahou, F., Tardivel-Lacombe, J., Stark, H., Schunack, W., Ganellin, C.R., Schwartz, J.C., and Arrang, J.M., Nature, 2000, vol. 408, no. 6814, pp. 860–864.
Rouleau, A., Ligneau, X., Tardivel-Lacombe, J., Morisset, S., Gbahou, F., Schwartz, J.C., and Arrang, J.M., Br. J. Pharmacol., 2002, vol. 135, no. 2, pp. 383–392.
Meye, F.J., Ramakers, G.M., and Adan, R.A., Transl. Psychiatry, 2014, vol.4.
Bond, R.A., Leff, P., Johnson, T.D., Milano, C.A., Rockman, H.A., McMinn, T.R., Apparsundaram, S., Hyek, M.F., Kenakin, T.P., Allen, L.F., and Lefkowitz, R.J., Nature, 1995, vol. 374, no. 6519, pp. 272–276.
Walwyn, W.M., Chen, W., Kim, H., Minasyan, A., Ennes, H.S., McRoberts, J.A., and Marvizon, J.C., J. Neurosci., 2016, vol. 36, no. 1, pp. 204–221.
Lecker, I., Yin, Y., Wang, D.S., and Orser, B.A., Br. J. Anaest, vol. 110, no. Suppl. 1, pp. i73–i81.
Savic, M.M., Clayton, T., Furtmüller, R., Gavrilovic, I., Samardzic, J., Savic, S., Huck, S., Sieghart, W., and Cook, J.M., Brain Res., 2008, vol. 1208, pp. 150–159.
Stamenic, T., Joksimovic, S., Biawat, P., Stankovic, T., Markovic, B., Cook, J.M., and Savic, M.M., J. Psychopharmacol., 2015, vol. 29, no. 9, pp. 1013–1024.
Chua, H.C. and Chebib, M., Adv. Pharmacol., 2017, vol. 79, pp. 1–34.
Olsen, R.W. and Sieghart, W., Pharmacol. Rev., 2008, vol. 60, no. 3, pp. 243–260.
Olsen, R.W., Adv. Pharmacol., 2015, vol. 73, pp. 167–202.
Sigel, E. and Steinmann, M.E., J. Biol. Chem., 2012, vol. 287, no. 48, pp. 40224–40231.
Sadee, W., Wang, D., and Bilsky, E.J., Life Sci., 2005, vol. 76, no. 13, pp. 1427–1437.
Sirohi, S., Dighe, S.V., Madia, P.A., and Yoburn, B.C., J. Pharmacol. Exp. Ther., 2009, vol. 330, no. 2, pp. 513–519.
Raehal, K.M., Lowery, J.J., Bhamidipati, C.M., Paolino, R.M., Blair, J.R., Wang, D., Sadee, W., and Bilsky, E.J., J. Pharmacol. Exp. Ther., 2005, vol. 313, no. 3, pp. 1150–1162.
Wang, D., Raehal, K.M., Lin, E.T., Lowery, J.J., Kieffer, B.L., Bilsky, E.J., and Sadée, W., J. Pharmacol. Exp. Ther., 2004, vol. 308, no. 2, pp. 512–520.
Alyautdin, R.N. and Romanov, B.K., Bezopasnost’ i risk farmakoterapii (Safety and Risk of Pharmacotherapy), 2014, no. 4, pp. 6–11.
Hodavance, S.Y., Gareri, C., Torok, R.D., and Rockman, H.A., J. Cardiovasc. Pharmacol., 2016, vol. 67, no. 3, pp. 193–202.
Evans, A.K. and Lowry, C.A., CNS Drug Rev, 2007, vol. 13, no. 4, pp. 475–501.
Sally, E.J., Xu, H., Dersch, C.M., Hsin, L.W., Chang, L.T., Prisinzano, T.E., Simpson, D.S., Giuvelis, D., Rice, K.C., Jacobson, A.E., Cheng, K., Bilsky, E.J., and Rothman, R.B., Synapse, 2010, vol. 64, no. 4, pp. 280–288.
Barbalho, C.A., Nunes-de-Souza, R.L., and Cantode-Souza, A., Brain Res., 2009, vol. 1267, pp. 65–76.
Hashimoto, T. and Iwamura, Y., Pharmacol. Biochem. Behav., 2016, vol. 144, pp. 45–52.
Hashimoto, T., Kiyoshi, T., Kohayakawa, H., Iwamura, Y., and Yoshida, N., Neuroscience, 2014, vol. 256, pp. 352–359.
Nutt, D.J., Besson, M., Wilson, S.J., Dawson, G.R., and Lingford-Hughes, A.R., Neuropharmacology, 2007, vol. 53, no. 7, pp. 810–820.
Barnard, E.A., Skolnick, P., Olsen, R.W., Mohler, H., Sieghart, W., Biggio, G., Braestrup, C., Bateson, A.N., and Langer, S.Z., Pharmacol. Rev., 1998, vol. 50. no. 2, pp. 291–313.
Ballard, T.M., Knoflach, F., Prinssen, E., Borroni, E., Vivian, J.A., Basile, J., Gasser, R., Moreau, J.L., Wettstein, J.G., Buettelmann, B., Knust, H., Thomas, A.W., Trube, G., and Hernandez, M.C., Psychopharmacology (Berlin), 2009, vol. 202, nos. 1–3, pp. 207–223.
Knust, H., Achermann, G., Ballard, T., Buettelmann, B., Gasser, R., Fischer, H., Hernandez, M.C., Knoflach, F., Koblet, A., Stadler, H., Thomas, A.W., Trube, G., and Waldmeier, P., Bioorg. Med. Chem. Lett., 2009, vol. 19, no. 20, pp. 5940–5944.
De Min, A., Matera, C., Bock, A., Holze, J., Kloeckner, J., Muth, M., Traenkle, C., De Amici, M., Kenakin, T., Holzgrabe, U., Dallanoce, C., Kostenis, E., Mohr, K., and Schrage, R., Mol. Pharmacol., 2017, vol. 91, no. 4, pp. 348–356.
Gbahou, F., Rouleau, A., Morisset, S., Parmentier, R., Crochet, S., Lin, J.S., Ligneau, X., Tardivel-Lacombe, J., Stark, H., Schunack, W., Ganellin, C.R., Schwartz, J.C., and Arrang, J.M., Proc. Natl. Acad. Sci. U.S.A., 2003, vol. 100, no. 19, pp. 11086–11091.
Riddy, D.M., Cook, A.E., Diepenhorst, N.A., Bosnyak, S., Brady, R., Mannoury la Cour, C., Mocaer, E., Summers, R.J., Charman, W.N., Sexton, P.M., Christopoulos, A., and Langmead, C.J., Mol. Pharmacol., 2017, vol. 91, no. 2, pp. 87–99.
Milic, M., Timic, T., Joksimovic, S., Biawat, P., Rallapalli, S., Divljakovic, J., Radulovic, T., Cook, J.M., and Savic, M.M., Behav. Brain Res., 2013, vol. 241, pp. 206–213.
Wallner, M., Hanchar, H.J., and Olsen, R.W., Proc. Natl. Acad. Sci. U.S.A., 2006, vol. 103, no. 22, pp. 8540–8545.
Haefely, W.E., Eur. Arch. Psychiatry Neurol. Sci., 1989, vol. 238, nos 5–6, pp. 294–301.
Olsen, R.W., Neurochem. Res., 2014, vol. 39, no. 10, pp. 1924–1941.
Mehta, A.K. and Ticku, M.K., J. Pharmacol. Exp. Ther., 1988, vol. 246, no. 2, pp. 558–564.
Mehta, A.K. and Ticku, M.K., J. Pharmacol. Exp. Ther., 1989, vol. 249, no. 2, pp. 418–423.
Wang, F., Xu, Z., Yuen, C.T., Chow, C.Y., Lui, Y.L., Tsang, S.Y., and Xue, H., Neuropharmacology, 2007, vol. 53, no. 4, pp. 574–582.
Clayton, T., Poe, M.M., Rallapalli, S., Biawat, P., Savic, M.M., Rowlett, J.K., Gallos, G., Emala, C.W., Kaczorowski, C.C., Stafford, D.C., Arnold, L.A., and Cook, J.M., Int. J. Med. Chem., 2015, vol. 2015, article ID 430248.
Hashimoto, T., Hatayama, Y., Nakamichi, K., and Yoshida, N., Eur. J. Pharmacol., 2014, vol. 745, pp. 123–128.
Möhler, H., Adv. Pharmacol., 2015, vol. 72, pp. 1–36.
Venault, P. and Chapouthier, G., Scientific World Journal, 2007, vol. 7, pp. 204–223.
Guerrini, G. and Ciciani, G., Expert Opin. Ther. Pat., 2013, vol. 23, no. 7, pp. 843–866.
Farrant, M. and Nusser, Z., Nat. Rev. Neurosci., 2005, vol. 6, no. 3, pp. 215–229.
Hoestgaard-Jensen, K., Dalby, N.O., Krall, J., Hammer, H., Krogsgaard-Larsen, P., Frolund, B., and Jensen, A.A., J. Neurosci., 2014, vol. 34, no. 49, pp. 16256–16272.
Jia, F., Chandra, D., Homanics, G.E., and Harrison, N.L., J. Pharmacol. Exp. Ther., 2008, vol. 326, no. 2, pp. 475–482.
Atack, J.R., Curr. Top. Med. Chem., 2011, vol. 11, no. 9, pp. 1203–1214.
Carreno, F.R., Collins, G.T., Frazer, A., and Lodge, D.J., Int. J. Neuropsychopharmacol., 2017, vol. 20, no. 6, pp. 504–509.
Redrobe, J.P., Elster, L., Frederiksen, K., Bundgaard, C., de Jong, I.E., Smith, G.P., Bruun, A.T., Larsen, P.H., and Didriksen, M., Psychopharmacology (Berlin), 2012, vol. 221, no. 3, pp. 451–468.
Atack, J.R., Pharmacol. Ther., 2010, vol. 125, no. 1, pp. 11–26.
Martínez-Cué, C., Delatour, B., and Potier, M.C., Neurosci. Biobehav. Rev., 2014, vol. 46., Pt. 2, pp. 218–227.
Cook, J.B., Foster, K.L., Eiler, W.J. 2nd., McKay P.F., Woods J., 2nd., Harvey S.C., Garcia M., Grey C., McCane S., Mason D., Cummings R., Li X., Cook J.M., and June H.L. Alcohol. Clin. Exp. Res., 2005, vol. 29, no. 8, pp. 1390–1401.
June, H.L., Torres, L., Cason, C.R., Hwang, B.H., Braun, M.R., and Murphy, J.M., Brain Res., 1998, vol. 784, nos. 1–2, pp. 256–275.
Liu, R., Hu, R.J., Zhang, P., Skolnick, P., and Cook, J.M., J. Med. Chem., 1996, vol. 39, no. 9, pp. 1928–1934.
Atack, J.R., Bayley, P.J., Fletcher, S.R., McKernan, R.M., Wafford, K.A., and Dawson, G.R., Eur. J. Pharmacol., 2006, vol. 548, nos. 1–3, pp. 77–82.
McKay, P.F., Foster, K.L., Mason, D., Cummings, R., Garcia, M., Williams, L.S., Grey, C., McCane, S., He, X., Cook, J.M., and June, H.L., Psychopharmacology (Berlin), 2004, vol. 172, no. 4, pp. 455–462.
Fischell, J., Van Dyke, A.M., Kvarta, M.D., LeGates, T.A., and Thompson, S.M., Neuropsychopharmacology, 2015, vol. 40, no. 11, pp. 2499–2509.
Samardzic, J., Puskas, L., Obradovic, M., Lazic-Puskas, D., and Obradovic, I.D., Acta Veterinaria-Beograd, 2014, vol. 64, no. 1, pp. 52–60.
Zanos, P., Nelson, M.E., Highland, J.N., Krimmel, S.R., Georgiou, P., Gould, T.D., and Thompson, S.M., eNeuro, 2017, vol. 4, no. 1, article e0285-16.2017.
Wallner, M. and Olsen, R.W., Br. J. Pharmacol., 2008, vol. 154, no. 2, pp. 288–298.
Corda, M.G., Giorgi, O., Mele, S., and Biggio, G., Brain Res. Bull., 1987, vol. 19, no. 3, pp. 379–385.
Kubova, H. and Mares, P., Naunyn Schmiedeberg’s Arch. Pharmacol., 1994, vol. 350, no. 4, pp. 393–397.
Nicolas, L.B. and Prinssen, E.P., Psychopharmacology (Berlin), 2006, vol. 184, no. 1, pp. 65–74.
Nutt, D.J., Lister, R.G., Rusche, D., Bonetti, E.P., Reese, R.E., and Rufener, R., Eur. J. Pharmacol., 1988, vol. 151, no. 1, pp. 127–129.
Tracy, M.E., Banks, M.L., and Shelton, K.L., Psychopharmacology (Berlin), 2016, vol. 233, no. 4, pp. 715–725.
Bonetti, E.P., Burkard, W.P., Gabl, M., Hunkeler, W., Lorez, H.P., Martin, J.R., Moehler, H., Osterrieder, W., Pieri, L., Polc, P., Richards, J.G., Schaffner, R., Scherschlicht, R., Schoch, P., and Haefely, W.E., Pharmacol. Biochem. Behav., 1988, vol. 31, no. 3, pp. 733–749.
Lister, R.G. and Nutt, D.J., Adv. Alcohol Subst. Abuse, 1988, vol. 7, nos. 3–4, pp. 119–123.
Suzdak, P.D., Paul, S.M., and Crawley, J.N., J. Pharmacol. Exp. Ther., 1988, vol. 245, no. 3, pp. 880–886.
Dar, M.S., Pharmacol. Biochem. Behav., 1992, vol. 42, no. 3, pp. 473–479.
Glowa, J.R., Crawley, J., Suzdak, P.D., and Paul, S.M., Pharmacol. Biochem. Behav., 1988, vol. 31, no. 3, pp. 767–772.
Nabeshima, T., Tohyama, K., and Kameyama, T., Eur. J. Pharmacol., 1988, vol. 155, no. 3, pp. 211–217.
Syapin, P.J., Gee, K.W., and Alkana, R.L., Brain Res. Bull., 1987, vol. 19, no. 5, pp. 603–605.
Hoffman, P.L., Tabakoff, B., Szabó, G., Suzdak, P.D., and Paul, S.M., Life Sci., 1987, vol. 41, no. 5, pp. 611–619.
Hanchar, H.J., Chutsrinopkun, P., Meera, P., Supavilai, P., Sieghart, W., Wallner, M., and Olsen, R.W., Proc. Natl. Acad. Sci. U.S.A., 2006, vol. 103, no. 22, pp. 8546–8551.
Benson, J.A., Löw, K., Keist, R., Mohler, H., and Rudolph, U., FEBS Lett., 1998, vol. 431, no. 3, pp. 400–404.
Lister, R.G. and Durcan, M.J., Brain Res., 1989, vol. 482, no. 1, pp. 141–144.
Durcan, M.J. and Lister, R.G., Pharmacol. Biochem. Behav., 1989, vol. 32, no. 3, pp. 667–670.
Sternfeld, F., Carling, R.W., Jelley, R.A., Ladduwahetty, T., Merchant, K.J., Moore, K.W., Reeve, A.J., Street, L.J., O’Connor, D., Sohal, B., Atack, J.R., Cook, S., Seabrook, G., Wafford, K., Tattersall, F.D., Collinson, N., Dawson, G.R., Castro, J.L., and Macleod, A.M., J. Med. Chem., 2004, vol. 47, no. 9, pp. 2176–2179.
ClinicalTrials.gov, Ability of partial inverse agonist, iomazenil, to block ethanol effects in humans. NCT01590277. https://doi.org/clinicaltrials.gov/ct2/show/NCT01590277.2017.
McBride, W.J., Murphy, J.M., Lumeng, L., and Li, T.K., Pharmacol. Biochem. Behav., 1988, vol. 30, no. 4, pp. 1045–1050.
Melón, L.C. and Boehm, S.L. 2nd, Behav. Brain Res., 2011, vol. 220, no. 1, pp. 230–237.
June, H.L., Greene, T.L., Murphy, J.M., Hite, M.L., Williams, J.A., Cason, C.R., Mellon-Burke, J., Cox, R., Duemler, S.E., Torres, L., Lumeng, L., and Li, T.K., Brain Res., 1996, vol. 734, nos. 1–2, pp. 19–34.
June, H.L., Harvey, S.C., Foster, K.L., McKay, P.F., Cummings, R., Garcia, M., Mason, D., Grey, C., McCane, S., Williams, L.S., Johnson, T.B., He, X., Rock, S., and Cook, J.M., J. Neurosci., 2001, vol. 21, no. 6, pp. 2166–2177.
Rüedi-Bettschen, D., Rowlett, J.K., Rallapalli, S., Clayton, T., Cook, J.M., and Platt, D.M., Alcohol. Clin. Exp. Res., 2013, vol. 37, no. 4, pp. 624–634.
Griffiths, J.L. and Lovick, T.A., Neuroscience, 2005, vol. 136, no. 2, pp. 457–466.
Lovick, T.A., Griffiths, J.L., Dunn, S.M., and Martin, I.L., Neuroscience, 2005, vol. 131, no. 2, pp. 397–405.
Korpi, E.R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D.J., Hyytiä, P., and Dawe, G.S., Pharmacol. Rev., 2015, vol. 67, no. 4, pp. 872–1004.
Buettelmann, B., Ballard, T.M., Gasser, R., Fischer, H., Hernandez, M.C., Knoflach, F., Knust, H., Stadler, H., Thomas, A.W., and Trube, G., Bioorg. Med. Chem. Lett., 2009, vol. 19, no. 20, pp. 5958–5961.
Hatayama, Y., Hashimoto, T., Kohayakawa, H., Kiyoshi, T., Nakamichi, K., Kinoshita, T., and Yoshida, N., Neuroscience, 2014, vol. 265, pp. 217–225.
Contestabile, A., Magara, S., and Cancedda, L., Front. Cell. Neurosci., 2017, vol. 11, article54.
Etherington, L.A., Mihalik, B., Pálvölgyi, A., Ling, I., Pallagi, K., Kertész, S., Varga, P., Gunn, B.G., Brown, A.R., Livesey, M.R., Monteiro, O., Belelli, D., Barkóczy, J., Spedding, M., Gacsályi, I., Antoni, F.A., and Lambert, J.J., Neuropharmacology, 2017, vol. 125, pp. 353–364.
Gacsályi, I., Móricz, K., Gigler, G., Wellmann, J., Nagy, K., Ling, I., Barkoczy, J., Haller, J., Lambert, J.J., Szénási, G., Spedding, M., and Antoni, F.A., Neuropharmacology, 2017, vol. 125, pp. 30–38.
Mihalik, B., Pálvölgyi, A., Bogár, F., Megyeri, K., Ling, I., Barkóczy, J., Bartha, F., Martinek, T.A., Gacsályi, I., and Antoni, F.A., Eur. J. Pharmacol., 2017, vol. 798, pp. 129–136.
Pálvölgyi, A., Móricz, K., Pataki, Á., Mihalik, B., Gigler, G., Megyeri, K., Udvari, S., Gacsályi, I., and Antoni, F.A., Neuropharmacology, 2018, vol. 128, pp. 408–415.
Atack, J.R., CNS Neurosci. Ther., 2008, vol. 14, no. 1, pp. 25–35.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © A.I. Golovko, M.B. Ivanov, E.S. Golovko, V.B. Dolgo-Saburov, E.P. Zatsepin, 2018, published in Neirokhimiya, 2018, Vol. 35, No. 3S, pp. S3–S14.
Rights and permissions
About this article
Cite this article
Golovko, A.I., Ivanov, M.B., Golovko, E.S. et al. The Neurochemical Mechanisms of the Pharmacological Activities of Inverse Agonists of the Benzodiazepine Binding Site. Neurochem. J. 12, 337–346 (2018). https://doi.org/10.1134/S1819712418030042
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712418030042